塞德斯医疗 CLDX 深 沪
等待开盘 10-06 09:30:00 美东时间
32.59
+0.940
+2.97%
华盛通- 最 高42.12
- 今 开31.83
- 成交量 108.68万股
- 最 低 30.38
- 昨 收 31.65
- 总市值 152.37万
- 52周最高 45.14
- 市盈率 静 --
- 换手率 2324.51%
- 52周最低 22.10
- 委 比 65.78%
- 总股本 4.68万
- 历史最高 582.60
- 量 比 0.61
- 振 幅 37.09%
- 历史最低 1.10
- 每 手 1
- 风险率 5.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
09-23 00:25
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.
07-22 19:29
Celldex CFO Sam Martin Plans To Retire In 2027
Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company’s Chief Financial
07-16 04:01
Celldex Therapeutics Commences Common Stock Offering; Terms Undisclosed
Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In addition, Celldex expects to
04-02 04:01
Celldex药物二期试验结果公布后股价重挫
美股周三早盘，生物技术公司Celldex Therapeutics（CLDX）股价重挫9.5%，其Barzolvolimab药物二期试验虽达到主要终点但未能改善嗜酸性食管炎（EoE）症状。结果表明肥大细胞并非EoE主要驱动因素，该结论影响投资者情绪导致其股价重挫。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-08-20 22:27
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
Barzolvolimab significantly improves angioedema in CSU patients, with 77% of treated patients angioedema-free at Week 52, demonstrating strong clinical benefit and enhanced quality of life.
2025-06-14 14:48
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Celldex will host a webcast on June 12 at 6:00 pm ET to discuss Phase 2 barzolvolimab data in chronic spontaneous urticaria. EAACI Congress 2025 will feature two presentations on June 13 and 14, highlighting efficacy, tolerability, and angioedema data, presented by Ana Giménez-Arnau, MD, PhD, and Martin Metz, MD.
2025-06-10 20:01
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
Celldex Therapeutics, Inc. announced that Denice M. Torres has been elected to its Board of Directors. Torres brings extensive leadership experience in pharmaceutical and consumer healthcare sectors, with a track record of driving strategic growth. She currently serves as CEO of The Ignited Company and previously held senior roles at Johnson & Johnson. Torres expressed enthusiasm for Celldex's progress with barzolvolimab and its potential to improve treatment options for patients.
2025-06-06 12:01
塞德斯医疗盘中异动 大幅拉升5.10%
北京时间2025年01月18日03时13分，塞德斯医疗（CLDX.us）股票出现波动，股价大幅上涨5.10%。截至发稿，该股报23.92美元/股，成交量34.6106万股，换手率0.52%，振幅5.72%。 最近的财报数据显示，该股实现营业收入3.19百万美元，净利润-42.12百万美元，每股收益-0.64美元，毛利2.41百万美元，市盈率-9.26倍。 机构评级方面，在所有12家参与评级的机构中，83%的券商给予买入建议，17%的券商给予持有建议，无券商给予卖出建议。 塞德斯医疗股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Channel Therapeutics Corpo...
2025-01-18 03:13
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
Across the recent three months, 10 analysts have shared their insights on Celld...
2024-09-26 01:01
